SEC Form 15-12G filed by Akero Therapeutics Inc.
$AKRO
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 001-38944
Akero Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
601 Gateway Boulevard, Suite 350
South San Francisco, CA 94080
(650) 487-6488
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
☒
|
|
|
Rule 12g-4(a)(2)
|
☐
|
|
|
Rule 12h-3(b)(1)(i)
|
☒
|
|
|
Rule 12h-3(b)(1)(ii)
|
☐
|
|
|
Rule 15d-6
|
☐
|
|
|
Rule 15d-22(b)
|
☐
|
Approximate number of holders of record as of the certification or notice date: One.
Pursuant to the requirements of the Securities Exchange Act of 1934, Akero Therapeutics, Inc. has caused this certification/notice to be signed on
its behalf by the undersigned duly authorized person.
|
Akero Therapeutics, Inc.
|
|||
|
Date:
|
December 19, 2025
|
By:
|
/s/ Jonathan Young
|
|
Jonathan Young, J.D., Ph.D.
|
|||
|
Assistant Treasurer
|
|||